معرفی
Professor Campbell Roxburgh is a Professor of Colorectal Surgical Oncology at the University of Glasgow, based at the Clinical Research Garscube facility and Glasgow Royal Infirmary. His work focuses on advancing understanding and treatment of colorectal cancer through rigorous clinical research with numerous collaborations across multiple institutions. He maintains an active research program with over 140 publications spanning from 2013 to 2025.
Professor Roxburgh's research interests span colorectal cancer, lower gastrointestinal tract diseases, and the intestinal/gut microbiome. His work particularly emphasizes the relationship between systemic inflammation and cancer outcomes, tumor microenvironment analysis, and surgical techniques for colorectal cancer treatment. He has developed and validated several prognostic scoring systems that help predict patient outcomes, most notably the Glasgow Microenvironment Score which has gained significant recognition in the field. His research integrates CT-derived body composition analysis with inflammatory markers to predict treatment response and survival outcomes.
His extensive publication record demonstrates consistent focus on biomarker development, surgical innovations, and understanding cancer biology. Recent work shows increasing emphasis on robotic-assisted surgery, the relationship between systemic inflammation and cancer cachexia, and novel biomarkers for predicting cancer recurrence. His work bridges basic science discoveries with clinical applications, contributing significantly to personalized cancer care.
Professor Roxburgh frequently collaborates with leading researchers including Donald McMillan, Paul Horgan, James Park, and Joanne Edwards. His research has significant clinical implications for improving surgical outcomes, predicting treatment response, and developing personalized treatment approaches for colorectal cancer patients.
He actively contributes to clinical decision-making frameworks, helping oncologists and surgeons determine optimal treatment approaches based on tumor characteristics and systemic inflammatory status. His work continues to advance the field of colorectal cancer research and treatment.
